Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3181-3200 of 3,900 trials

Refractory Solid Tumors: Propranolol and Vinorelbine Study

We are testing a combination of Propranolol and Vinorelbine in children and teenagers with hard-to-treat solid tumors. The study aims to find the safest dose and evaluate how well this treatment works over time.

Malignant GliomaMalignant Solid TumorDesmoid Tumor>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Ozone Treatment for Numbness from Chemotherapy

We are studying whether adding ozone therapy helps reduce numbness and tingling in patients with chemotherapy-induced nerve damage. The trial also looks at how this treatment affects overall quality of life and costs.

Chemotherapy-Induced Peripheral Neuropathy6-12 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsStandard MedicinesInternal MedicineNeurologyOncology

Schizophrenia Treatment: Cannabidiol vs. Placebo

We are studying whether adding cannabidiol to standard antipsychotic treatment helps improve recovery in early schizophrenia. The trial will also look at safety and changes in mental and social functioning.

Remitted Schizophrenia1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Advanced Lung Cancer: Atezolizumab vs. Atezolizumab Plus Bevacizumab

We are studying whether adding bevacizumab to atezolizumab helps patients with advanced non-small-cell lung cancer live longer than using atezolizumab alone. This trial is for those with high PD-L1 expression who have not yet received treatment.

Advanced Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Pembrolizumab for Advanced Adrenocortical Carcinoma

We are studying whether pembrolizumab can effectively treat advanced, progressive adrenocortical carcinoma. The trial also looks at its safety and how it affects patients' quality of life.

Adrenocortical Carcinoma6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

Alzheimer’s Disease: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve memory and daily activities in patients with mild cognitive impairment and Alzheimer's disease. This study will also assess its effects on brain health and quality of life.

Alzheimer's Disease1-2 yearsEfficacy phase (II)Standard MedicinesNeurologyPsychiatry

Multiple Myeloma: Isatuximab Treatment Study

We are studying a new treatment combination for elderly patients with newly diagnosed multiple myeloma who cannot undergo a transplant. The goal is to see if this approach improves disease control and safety compared to standard treatments.

Newly Diagnosed Multiple Myeloma in Elderly Patients>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Crohn's Disease: Cellvizio Imaging Study

We are testing a new imaging technique during surgery for Crohn's disease to help identify healthy tissue margins. This may improve surgical outcomes by ensuring enough healthy tissue is removed.

Crohn's Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

NSTEMI Treatment: Aspirin vs. Aspirin and Fondaparinux

We are comparing the effects of aspirin alone to a combination of aspirin and fondaparinux in patients with NSTEMI. This study aims to see which treatment is more effective and safer before invasive procedures.

Non-ST-Elevation Myocardial Infarction (NSTEMI)>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Colorectal Cancer: MK-1084 Treatment Study

We are testing a new treatment combining MK-1084, cetuximab, and chemotherapy for patients with advanced colorectal cancer. The goal is to see if this combination is safer and more effective than standard treatments.

Metastatic Colorectal CancerKRAS Mutation>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Unruptured Intracranial Aneurysms: Low-Dose Aspirin and Blood Pressure Management

We are studying whether a treatment plan with low-dose aspirin and strict blood pressure control can lower the risk of aneurysm rupture or growth in patients with unruptured intracranial aneurysms. This trial compares this approach to standard care to see if it offers better outcomes.

Unruptured Intradural Aneurysm>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCardiologyNeurology

MDS and CMML: PXS-5505 with 5-Azacitidine

We are studying a new treatment combining PXS-5505 and 5-Azacitidine for patients with MDS and CMML. The goal is to evaluate its safety and effectiveness compared to standard therapies.

Myelodysplastic Neoplasms and Chronic Myelomonocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)HematologyOncology

Sinusitis Treatment: Azithromycin Study

We are testing whether a three-month course of azithromycin improves quality of life for adults with idiopathic purulent oedematous sinusitis. The study will compare its effects to a placebo and evaluate treatment tolerance.

Bacterial SinusitisChronic Sinusitis>2 yearsConfirmation phase (III)Investigational MedicinesOtolaryngology

SOD1 ALS: AMT-162 Gene Therapy

We are testing a new gene therapy for adults with SOD1 amyotrophic lateral sclerosis to see if it is safe and well-tolerated. We’re also exploring its potential effects on the disease.

Amyotrophic Lateral Sclerosis (ALS)>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Rare Cancers: Domvanalimab + Zimberelimab Study

We are investigating the safety and effectiveness of a new combination therapy for patients with advanced rare cancers that have not responded to previous treatments. This trial includes several types of rare cancers, aiming to find better treatment options.

Rare Cancers>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Anti-Infection Drugs: Healthy vs. Severely Burned Patients

We are investigating how the body processes anti-infection drugs in healthy people compared to those with severe burns in the ICU. This study aims to improve treatment strategies for burn patients.

Burns>2 yearsSafety phase (I)DermatologyInfectious DiseasesInternal Medicine

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology